Lengthening the duration of response execution does not modulate blindness to action-compatible stimuli.

2003 ◽  
Vol 57 (1) ◽  
pp. 11-22 ◽  
Author(s):  
Chris Oriet ◽  
Biljana Stevanovski ◽  
Pierre Jolicœur ◽  
William B. Cowan
Keyword(s):  
Duration Of Response ◽  
Response Execution

scholarly journals Action monitoring fails when motor execution is too fast: no time for correction

2020 ◽  
Author(s):  
Ramdani ◽  
emmanuel sagui ◽  
bruno schmid ◽  
olivier castagna ◽  
Karen Davranche ◽  
...  
Keyword(s):  
Mechanical Response ◽  
Incorrect Response ◽  
Time Interval ◽  
Information Processing Model ◽  
Action Monitoring ◽  
Dependent Variables ◽  
Duration Of Response ◽  
Response Execution ◽  
Peripheral Motor ◽  
S Model

A recent information processing model of two-choice RT situations (Servant et al., 2015), suggests that conditions which reduce the duration of peripheral motor processes, should also reduce the efficiency of the action monitoring system, because letting no time enough for correction of partial errors (i.e. subthreshold transient muscle activity of the agonists of the incorrect response preceding the correct response). A physiological situation, namely sustained physical exercise, has repeatedly been reported to reduce the duration of response execution. Therefore, in order to test the prediction of the model, we compared action monitoring efficiency between a sustained exercise (59.42% of MAP) and a control (15 W) condition in the same subjects while they were performing a Simon task. Electromyographic (EMG) recordings of muscles implicated in the response allowed to measure premotor time (time interval between the stimulus and the onset of the EMG burst) and motor time (MT, time interval between the onset of the EMG burst and the mechanical response, which gives access to response execution processes). Electromyogram further permitted to unmask partial errors. Correction ratio was calculated by dividing the number of partial errors by the number of incorrect activations (partial errors + errors). As expected, exercise decreased MT. In addition, exercise reduced the correction ratio. Furthermore, there was a positive inter-subject correlation between these two dependent variables. In line with Servant et al.'s model (2015), we propose that the drop in the efficiency of cognitive control was due to insufficient MT available for action monitoring to operate when incorrect activations were produced.

Faster Choice-Reaction Times to Positive than to Negative Facial Expressions

2003 ◽  
Vol 17 (3) ◽  
pp. 113-123 ◽  
Author(s):  
Jukka M. Leppänen ◽  
Mirja Tenhunen ◽  
Jari K. Hietanen
Keyword(s):  
Facial Expressions ◽  
Cognitive Processing ◽  
Response Selection ◽  
Reaction Times ◽  
Happy Face ◽  
Response Onset ◽  
Response Execution ◽  
Onset Response ◽  
Positive Stimuli ◽  
Choice Reaction Times

Abstract Several studies have shown faster choice-reaction times to positive than to negative facial expressions. The present study examined whether this effect is exclusively due to faster cognitive processing of positive stimuli (i.e., processes leading up to, and including, response selection), or whether it also involves faster motor execution of the selected response. In two experiments, response selection (onset of the lateralized readiness potential, LRP) and response execution (LRP onset-response onset) times for positive (happy) and negative (disgusted/angry) faces were examined. Shorter response selection times for positive than for negative faces were found in both experiments but there was no difference in response execution times. Together, these results suggest that the happy-face advantage occurs primarily at premotoric processing stages. Implications that the happy-face advantage may reflect an interaction between emotional and cognitive factors are discussed.

scholarly journals Radioembolization for Metastatic Colorectal Cancer

2021 ◽  
Author(s):  
David Guez ◽  
Patrick D. Sutphin ◽  
Suvranu Ganguli
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Salvage Treatment ◽  
Review Article ◽  
Prognostic Indicators ◽  
Common Site ◽  
First Line ◽  
Resistance To Therapy ◽  
Duration Of Response ◽  
Dominant Disease

AbstractThe liver is the most common site of metastatic disease in colorectal cancer, and, in the setting of liver-dominant disease, a chief contributor to mortality. Chemotherapy is the backbone of treatment for metastatic colorectal cancer; however, the duration of response is limited and resistance to therapy inevitably develops. Radioembolization represents a targeted treatment to the liver which has been studied in first-line, second-line, and in salvage treatment. Therapeutic rationale, outcomes, and prognostic indicators are presented in this systematic review article.

scholarly journals Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis

2021 ◽  
Author(s):  
Irene Bargellini ◽  
Valentina Lorenzoni ◽  
Giulia Lorenzoni ◽  
Paola Scalise ◽  
Gianni Andreozzi ◽  
...  
Keyword(s):  
Propensity Score ◽  
Tumor Progression ◽  
Tumor Response ◽  
Complete Response ◽  
Tumor Burden ◽  
Local Tumor Control ◽  
Lower Number ◽  
Tumor Control ◽  
Duration Of Response

Abstract Objectives To retrospectively compare long-term outcomes of first-line drug-eluting particle (DEB)- transarterial chemoembolization (TACE) and lipiodol-TACE, in patients with unresectable hepatocellular (HCC). Methods We retrospectively reviewed our database to identify adult patients with treatment-naïve unresectable HCC, who underwent TACE from 2006 to 2013. Patients were excluded in the absence of complete medical records relative to first TACE, 1-month follow-up, and/or sufficient follow-up data. Periprocedural complications, duration of hospitalization, 1-month tumor response by mRECIST, time to tumor progression (TTP) and target tumor progression (TTTP), and overall survival (OS) were evaluated. Results Out of an initial series of 656 patients, 329 patients were excluded for unavailability of sufficient baseline and/or follow-up data. The remaining 327 patients underwent either lipiodol-TACE (n = 160) or DEB-TACE (n = 167). Patients treated with lipiodol-TACE had a significantly higher tumor burden. By propensity score, patients were matched according to baseline differences (BCLC stage, uninodular or multinodular HCC, and unilobar or bilobar HCC), resulting in 101 patients in each treatment group. Lipiodol-TACE was associated with a significantly higher incidence of adverse events (p = 0.03), and longer hospitalization (mean, 2.5 days vs 1.9 days; p = 0.03), while tumor response, TTP, and OS were comparable. In patients achieving 1-month complete response (CR) of target tumor, TTTP was significantly (p = 0.009) longer after DEB-TACE compared to lipiodol-TACE (median, 835 vs 353 days), resulting in a lower number of re-treatments during the entire follow-up (0.75 vs 1.6, p = 0.01). Conclusion Compared to lipiodol-TACE, DEB-TACE offers higher tolerability, reduced hospitalization, and more durable target tumor response after CR. Key Points • Compared to lipiodol-TACE, DEB-TACE is better tolerated and has reduced side effects, which translates into shorter hospitalization. • When complete radiological response according to the mRECIST is obtained 1 month after the procedure, DEB-TACE offers a more durable local tumor control compared to lipiodol-TACE. • In these patients, the longer duration of response after DEB-TACE translates into a lower number of re-interventions.

474 Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: one institutional experience in Taiwan since 2016

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A505-A505
Author(s):  
Jo-Pai Chen ◽  
Wei-Chen Lu ◽  
Ruey-Long Hong
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clinical Benefit ◽  
Response Rate ◽  
University Hospital ◽  
List Type ◽  
Duration Of Response ◽  
Institutional Experience

BackgroundEsophageal squamous cell carcinoma is still a health burden in Taiwan. In R/M setting, the prognosis becomes worse. ESCC is still an immunogenic cancer. In randomized 2nd line ATTRACTION-3 study(nivolumab vs taxane after PF failure), median OS improved from 8.4 months in chemotherapy to 10.9 months in nivolumab(HR, 0.77; 95% CI, 0.62–0.96; p =0.019). The median duration of response was 3.9 months and 6.9 months. Nivolumab is a new 2nd line option for ESCC.MethodsFrom early 2016 to early 2020, 15 advanced ESCC patients had ever received immunotherapy-containing regimens in Yun-lin Branch of National Taiwan University Hospital and were analyzed.ResultsThe overall response to immunotherapy-containing regimens was 60%(9/15) and clinical benefit was 80%(12/15). 2nd line nivolumab was given in 3 cases; response rate was33% and clinical benefit was 67%. 2nd line afatinib combined with anti-PD1 was given in 9 case; response rate was 67% and clinical benefit was 78%. The response rate of 2nd line afatinib & pembrolizumab was 75%(3/4); however, Gr. III pneumonitis & Gr. II hepatitis were noted in the patient with progression. The response rate of 2nd line afatinib & nivolumab was 60%(3/5) and clinical benefit was 80%(4/5); skin rash and diarrhea were often found. 1st line afatinib combined with anti-PD1 was given in 3 patients; response rate was 67% and clinical benefit was 100%. The response rate of 1st line afatinib & nivolumab was 100%(2/2).ConclusionsEGFR TKIs have multiple immuno-modulatory effects and may increase immunotherapy benefits in ESCC. Anti-PD1 and anti-CTLA4, another possible rationale, could bring more benefits maybe in 1st line CheckMate649 study.AcknowledgementsNilTrial RegistrationN/AEthics ApprovalN/AConsentWritten informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.ReferencesNil

scholarly journals Motor-response execution versus inhibition alters social-emotional evaluations of specific individuals

2021 ◽  
Vol 215 ◽  
pp. 103290
Author(s):  
Rachel L. Driscoll ◽  
Elizabeth M. Clancy ◽  
Mark J. Fenske
Keyword(s):  
Motor Response ◽  
Social Emotional ◽  
Response Execution
Sign in / Sign up

Export Citation Format

Share Document